Condition
Stage I Oral Cavity Squamous Cell Carcinoma
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
100.0%
3 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 2 (1)
Trial Status
Terminated3
Clinical Trials (3)
Showing 3 of 3 trials
NCT02827838Early Phase 1Terminated
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
NCT03090412Phase 2TerminatedPrimary
Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer
NCT02334319Phase 1Terminated
Ganetespib Window of Opportunity Study in Head and Neck Cancers
Showing all 3 trials